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INTRODUCTION
Psychological stress can be defined as any uncomfortable emotion accompanied by predictable biochemical, physiological and behavioral changes (1) . All normal individuals experience stress, but significant variations are found in different age, gender and socioeconomic groups (2) . Along with interpersonal, home, family, work and social stressors, chronic physical disease can also result in stress and psychological disability (3, 4) . Acute stress, such as that experienced during examinations and sporting events, can have positive benefits. However, the stress response may become maladaptive if continuously activated, potentially resulting in immunosuppression, autonomic and enteric nervous system alterations, intestinal permeability and other inflammatory changes that may ultimately lead to chronic disease, including cardiovascular, respiratory and immune mediated disorders (5, 6 ).
Crohn's disease and ulcerative colitis are inflammatory bowel diseases (IBDs) that are associated with relatively high rates of psychological dysfunction when subjects are compared with population controls (7, 8) . Stress, anxiety and depression place a significant burden on IBD patients (9) and, although the link between stress and IBD has been contentious (10) , recent data indicate that psychological dysfunction may be causally associated with both onset and subsequent IBD activity (11, 12) . A nationwide registry study demonstrated that young Swedish males with low stress resilience had a modest increase in IBD diagnoses in later adulthood (11) , while a longitudinal study showed that anxious IBD patients with quiescent disease at baseline subsequently experienced relatively high rates of disease flares and an increased requirement for treatment escalation (12) . Acknowledging the relationship between IBD and psychological disability, Williet et al. have stressed the value of mental health indices as patient reported outcomes in clinical trials (13) , while psychological services are now considered an essential component of contemporary IBD therapy (14, 15) .
Several treatments are available for reducing psychological dysfunction, including stress, in clinical practice and these interventions have been systematically and critically reviewed in IBD subjects (16, 17) . They include educational programs, simple stress management and relaxation strategies, hypnotherapy, mindfulness-based stress reduction treatments and cognitive behavioral therapy (CBT). Both Gracie et al. and Knowles et al. conclude that some may have modest benefits in IBD populations while CBT appears to have a more positive impact on psychological health (16, 17) .
However, these authors also identified substantial limitations to virtually all interventional studies performed to date. Many were underpowered, uncontrolled, non-randomized, without inclusion or exclusion criteria or protocols for managing missing results. In addition, most failed to include data on psychiatric history or antidepressant use, IBD disease type and location, medications, disease activity, program protocols or course personnel information, thereby limiting reproducibility in research and clinical practice.
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Acceptance and Commitment Therapy (ACT) belongs to the family of behavioral and cognitive therapies (18) and its primary aim is to encourage subjects to adopt positive life values and to accept adverse experiences, including thoughts, feelings and sensations that are an inevitable consequence of life (19) . Although ACT and CBT overlap in some ways, ACT does not attempt to eliminate or modify negative thoughts or feelings, but rather encourages the subject to accept that these exist while simultaneously fostering a commitment to move towards values that have been identified and adopted by the individual. ACT uses a range of training exercises to help subjects become open, aware and active, and ultimately develop what psychologists refer to as "psychological flexibility". This can be defined as the ability to contact the present moment more fully as a conscious human being and to change, or persist in, behavior when doing so serves valued ends (20) . Comprehensive reviews of the ACT therapy model and it's use in clinical practice are available (21, 22) . ACT has been shown to reduce psychological dysfunction in several chronic disease states and has been effectively used in both Western and Eastern cultures (22, 23) , although it has not previously been investigated in IBD populations. The aim of this study was to assess the impact of an ACT program on stress in IBD subjects.
MATERIALS AND METHODS

Ethics
This randomized controlled study was conducted at a single academic teaching hospital in Dublin, Ireland between March 2015 and January 2017 (ClinicalTrials.gov ID NCT02350920). Approval was granted by the institutional Ethics Committee (St Vincent's University Hospital EC) and study participants provided written informed consent. All authors had access to the study data and approved the final manuscript.
Study Design
Eligible subjects were randomly assigned 1:1 to a group receiving a structured 8-week ACT course in addition to standard IBD medical care or to a control group that received only standard IBD medical care during the study. A stratified randomization procedure was used with subjects allocated to treatment and control groups according to gender and disease type using a webbased randomization protocol by a researcher not involved in recruitment.
Procedure
The ACT program consisted of eight 90-minute weekly sessions in groups of 14 to 16 participants.
The course manual was based on contemporary ACT models and tailored towards IBD patients with an emphasis on reducing stress, and all program materials are available in the supplementary section. A single experienced psychologist who was a peer reviewed ACT trainer provided all M A N U S C R I P T
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interventions. Each treatment session was observed and rated by an independent psychologist to assess the therapists' adherence to the treatment protocol.
Participants
IBD subjects with psychosocial dysfunction at screening, based upon a perceived stress score of 5 or more using a scale ranging from 1 to 10 (24) or a quality of life score of greater than 80 on a scale ranging from 0 to 400 (with higher scores indicating a poorer quality of life) (25) , were eligible for study. Subjects were recruited between March 2015 and October 2016 and had a radiological and histological diagnosis of Crohn's disease or ulcerative colitis. Participants aged between 18 and 65 years with inactive or stable mildly active disease as defined by a physician based upon symptoms, physical examination and laboratory blood tests, and incorporating the short Crohn's disease activity index or short Mayo score during the assessment as appropriate (26, 27) were eligible. Pregnant females, subjects previously exposed to a stress management program, those attending psychiatric or psychological services or receiving antidepressant medication were excluded from study. Steroids were not permitted in the three months prior to screening due to their potential psychological and endocrinological effects and subjects were required to be on stable doses of all IBD medications at screening for a minimum of three months.
Data Collection, Follow-up and Outcomes
Subjects were evaluated at baseline (week 0), post-intervention (week 8) and three months post intervention (week 20). Participants completed a baseline questionnaire assessing demographic, socioeconomic and clinical details. Subjects then completed a series of psychological questionnaires. The primary outcome measure, stress, was assessed using the Depression Anxiety and Stress Scales (DASS-21). This instrument consisted of a set of three 7 item depression, anxiety and stress survey tools (28) . A four-point Likert scale ranging from 0 (did not apply to me at all) to 3 (applied to me very much, or most of the time) was used to rate extent of stress, anxiety and depression over the previous week. Scores were doubled and summed to give a range of stress from 0 to 42 with higher scores indicating higher levels of distress (29) . A secondary stress measure, perceived stress, was assessed using a validated visual scale that asked the question "Please circle the number (0-10) on the "stressometer" that best describes how much stress you have experienced over the past week" (24) . Subjects also completed a modified practical and family problem list (30) to identify 13 potential stressors, including disease, diet, exercise, work/school, finance/money, housing, transportation, sexual relationships, dealing with partner, children and close relatives, social life and dealing with friends over the previous week. A free text section allowed individuals to comment on additional stressors that might not have been covered in the above list and these were later coded into the appropriate stressor categories. The 13 categories were collapsed into 6 groups for analysis to include i) disease, ii) Diet/exercise, iii) M A N U S C R I P T
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Work/home/finance/travel iv) Partner/sexual relationships, v) Children/close relatives and vi) Friends/social life.
Psychological flexibility was assessed using the Acceptance and Action Questionnaire (AAQ-II), a 7-item self-report scale in which subjects rated seven statements from 1 (never true) to 7 (always true) indicating the degree to which they avoided thoughts and feelings and adjusted their behavior in the presence of difficult emotions (31) . The AAQ yielded a total score between 7 and 49 and scores were reversed so that low scores indicated experiential avoidance (psychological inflexibility) and high scores relative psychological flexibility. Subjects in the ACT treatment group also completed the survey at each study visit to assess week-to-week psychological flexibility changes.
Quality of life was measured using the Short Health Scale (25, 32) . This validated IBD specific instrument consists of four 100 mm visual analogue scales evaluating IBD symptom burden, functional status as assessed by interference with activities of daily life, disease-related worry and general well-being. Disease activity was evaluated using the short Crohn's disease activity index and the short Mayo score (26, 27) . Blood was taken for analysis of C-reactive protein, hemoglobin, leucocyte and serum albumin concentration, and stool samples collected for fecal calprotectin concentration measurement at weeks 0, 8 and 20. Hair samples were taken at baseline and week 20 to assess hair cortisol concentration. Hair strands were cut from the posterior vertex as close to the scalp as possible, wrapped in tin foil and stored in a dark and dry place until shipment. (33) .
Hair grows at a speed of about 1cm per month and the scalp nearest hair segment of approximately 3cm, representing the average cortisol accumulated over a time span of 3 months before sampling (34), was retained. Following washing and sample extraction (35) , cortisol, testosterone, and progesterone concentrations were measured using liquid chromatography tandem mass spectrometry as previously described (36) . Cortisol values were standardized to the weight of the respective sample and results presented as pg/mg hair. Cases were excluded when less than 3.75 mg of material was available. Hair testosterone and progesterone levels were measured at baseline as internal controls with the expectation that these levels would be higher in male and female subjects respectively.
Statistical Analysis
To allow for a 40% attrition rate, and to have an 80% power to detect a between-group difference effect size of 0.6, the a priori estimated sample size was 120 (60 per group). Cohen's d = 0.66, based on the between-group difference in the existing ACT literature across all diagnoses (37) .
The primary analysis was complete case intention to treat and included all 79 subjects for whom data were available at weeks 0, 8 and 20. A per-protocol analysis of psychological variables was M A N U S C R I P T
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also performed including participants who attended five or more ACT sessions. Four subjects, who attended 0, 1, 3 and 4 sessions respectively, were excluded from this secondary analysis.
Parametric summary data are presented as means and standard deviations (SD) or 95 percent confidence intervals (CI), and non-parametric data are expressed as medians and interquartile ranges (IQR). Student's t-test, the Mann-Whitney U test and the Chi-square test were used to assess group equivalence at baseline. Correlations were analyzed using Spearman's rank correlation coefficient [r s ]. A mixed 3 (time) x 2 (treatment group) ANOVA, with time as the within subject factor and treatment group as the between-subjects factor, was used to assess the effect of ACT treatment on primary and secondary outcomes. The Greenhouse-Geisser method was used to calculate F values. A log transformation was applied to non-parametric data prior to analysis. The Statistical Package for the Social Sciences (SPSS 24.0; SPSS, Chicago, Illinois) was used for all analyses and two-tailed p values <0.05 were considered statistically significant.
RESULTS
Baseline characteristics
One hundred twenty-two subjects were randomized to the treatment (n=61) and control (n=61) groups ( Figure 1 ). Twenty-one withdrew from the study, and a further 22 failed to attend one of their follow-up visits at either week 8 (n=14) or week 20 (n=8). Study drop-out was not associated with any demographic, clinical, biochemical or psychological variable. Baseline data of the 79 participants included in the primary analysis are shown in Table 1 and were similar in both groups.
Twenty two patients (28%) had previously had a bowel resection, while 37 (47%) were on 5-ASA agents, 28 (35%) on an immune modulator and 20 (25%) on a biologic agent at the time of study.
Subjects did not report any adverse effects during or after ACT therapy and the independent course rater indicated that the specific goals and techniques for each session were covered and reported "excellent fidelity to the protocol" for all sessions.
Evaluation of the primary endpoint: Stress
In the intention to treat analysis, the mixed ANOVA indicated a significant treatment group x time interaction for changes in DASS-21 stress measurement over the study period (F=7.19, p=0.001)( Figure 2 , Table 2 ). Post-hoc analyses indicated that baseline stress levels were similar in control and treatment groups (p=0.82). There was a 39% reduction in stress from baseline in the treatment group at 8 weeks (p=0.01 v's control) and 45% at 20 weeks (p=0.004), with a significant overall decrease in stress levels in the treatment group over time (p<0.001). Stress decreased by 8% and 11% in the control group at 8 and 20 weeks respectively, but these changes were not significant (p=0.23). The results of the per protocol analysis were comparable, with a 43% and 49% reduction in stress in the treatment group from baseline to 8 and 20 weeks (Table 2 ). Table 3 shows that subjects in both the treatment and control groups continued to report the presence of M A N U S C R I P T
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multiple stressors over the 20-week study and that the prevalence of individual stressors did not change over time.
Evaluation of secondary endpoints: Perceived stress, anxiety, depression and quality of life domains
In the intention to treat analysis, there was a significant treatment x group interaction for changes in perceived stress (F=3.39, p=0.036)( Table 2) , with a 25% and 27% reduction from baseline to 8 and 20 weeks in the ACT group (p=0.005 and p=0.021 v's control respectively). This represented an overall decrease in perceived stress in the treatment (p<0.001), but not the control group (p=0.21) over time. The per protocol analysis provided comparable results with a 28% and 30% reduction in perceived stress in the ACT group from baseline to 8 and 20 weeks respectively (Table 2 ). In the intention to treat analysis, anxiety levels decreased by 29% and 31% in the treatment group and by 14% and 4% in the control group at weeks 8 and 20 respectively. There was no overall significant group x time interaction for change in anxiety (F=0.95, p=0.388) and the per protocol analysis yielded equivalent results (Table 2 ). In the intention to treat analysis, there was a significant group x time interaction for change in depression (F=4.79, p=0.010)( Table 2 ).
Depression scores decreased by 47% and 45% in the ACT group from baseline to 8 and 20 weeks respectively (p<0.001). In the per protocol analysis, depression scores decreased by 51% and 49% from baseline to week 8 and 20 (Table 2 ). Table 2 also shows the association between treatment and changes in the four quality of life domains over time. General wellbeing improved by 28% and 30% in the treatment group from baseline to 8 and 20 weeks, but the treatment x group interaction for change in general wellbeing was not significant (F=2.72, p=0.069). In the per protocol analysis, general wellbeing improved by 35% and 38% in the treatment group from baseline to 8 and 20 weeks with a significant treatment x group interaction (F=4.91, p=0.009), while there was a decrease in disease related worry of 33% and 44% in the treatment group from baseline to 8 and 20 weeks with a marginal treatment x group interaction (F=3.02, p=0.052). No change in symptom burden nor ability to carry out activities of daily life were seen over the study period ( Table 2) .
Evaluation of secondary endpoints: Disease activity
The Crohn's disease activity index, short Mayo score and fecal calprotectin levels remained stable over time in both treatment and control groups and there were no significant group x time Crohn's disease activity index (F=1. 23 
Evaluation of secondary endpoints: Hair cortisol concentration
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Baseline results were available for hair testosterone, progesterone and cortisol concentrations on 82, 97 and 92 of the 122 original study subjects respectively, and all available data were included in the baseline analyses. Baseline hair testosterone levels were 247% higher in males than females, while progesterone levels were 54% higher in females ( Figure 3A and B). Males and females had similar baseline cortisol concentrations (p=0.618) (data not shown). Baseline hair progesterone concentration was inversely associated with age in females (Spearman's rank correlation coefficient (r s ) -0.339; p=0.008) while testosterone levels appeared to be only marginally reduced in older males (r s -0.311; p=0.069) (data not shown). Figure 3C shows that baseline hair cortisol levels correlated positively with stress (p=0.050) and anxiety (p=0.046), but not depression (p=0.221). Hair cortisol concentration data were available for 51 subjects both at baseline and 20 weeks and no significant treatment group x time interaction for changes in cortisol levels was found over the study (F=0.046, p=0.831)( Figure 3D ).
ACT and stress reduction: Potential mechanism of action
To determine if ACT therapy improves emotional wellbeing by increasing psychological flexibility, we assessed changes in psychological flexibility over the eight ACT sessions in the 33 treatment patients included in the per protocol group. Figure 4A shows that there was an increase in psychological flexibility commencing after the third ACT session and that this continued to increase steadily over the latter sessions (p<0.001). Figure 4B indicates a significant inverse correlation between psychological flexibility and stress over the 20 week study, with positive changes in psychological flexibility associated with a reduction in stress (r -0.517, p=0.002).
DISCUSSION
In this randomized controlled trial, an eight week ACT course resulted in a 45% reduction in stress three months after the intervention and a 49% reduction in those subjects adherent to the ACT protocol. In addition, positive effects were found on perceived stress and depression while therapy also appeared to have some impact on the general wellbeing quality of life domain, at least in those adherent to the protocol. In contrast, no significant treatment effect was found on anxiety levels over the study, although it should be noted that subjects were not selected based on preexisting anxiety and that the relatively low baseline levels may have made it less likely that a post treatment difference in groups could be detected. Overall, the improvement in each of the psychological variables studied, from between 27% and 45% in the intention to treat analysis at the 20 week follow-up visit, suggests that ACT may be an effective therapy for IBD patients with psychological dysfunction.
In addition to the subjective evaluations reported here, an objective stress assessment was made using hair cortisol concentrations at baseline and at the 20 week follow-up visit. Hair cortisol serves as a prolonged stress diary and smooths out diurnal steroid fluctuations and variations caused by M A N U S C R I P T
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transient stressors (33) . The data show a positive relationship between cortisol concentrations and both stress and anxiety, but not depression, at baseline. However, a decline in hair cortisol concentration in line with subjective stress was not found. A recent study of normal subjects, newly qualified doctors followed over their year-long internship, found changes in hair cortisol over time, but without a direct association with self-reported depression or stress (38) , and the precise relationship between changes in subjective and objective stress markers remains to be determined. Gao et al. have suggested that hair cortisol concentrations may react more slowly to changes in psychological stress than subjective measurements (39) , and it is likely that any possible change in the present study might have been observable only some time after the 20-week follow-up period ended. A recent meta-analysis found that hair cortisol concentrations are increased by 40 percent or more under conditions of chronic stress (40) , although correlations between subjective stress reports and hair cortisol concentrations are inconsistent. This may be due to inherent differences in an individuals' psychological or physiological reaction to an acute stressor or contrasting levels of inherent stress resilience. Nevertheless, the results provide helpful benchmark data for future researchers investigating the longer-term nature of the stress-cortisol relationship in IBD subjects, while the hair testosterone and progesterone results also provide valuable quality control information.
The ACT model is adaptable, and programs can be tailored to help change a diverse range of ineffective behavior patterns in chronic disease subjects (23) . The intervention used in the present study was designed specifically to target and modify the stress response in IBD subjects. There was no appreciable change in the number or nature of the stressors experienced by subjects in this study before or after the ACT program and it is likely that the psychological gains resulted largely from augmented coping mechanisms rather than a decrease in the sources of stress. ACT programs impact positively on mental health function in other chronic diseases and in normal subjects, probably mediated by an increase in psychological flexibility that ultimately increases the subject's resilience to stress (41) . Studies in social workers (42) and other working individuals (43) indicate that improvements in stress are closely linked to changes in psychological flexibility and occur because ACT changes the focus from symptom reduction to enhancing psychological flexibility processes such as engagement in acceptance and mindfulness while embracing valued behaviors. Our data, linking stress and psychological flexibility suggest that this is also the case for IBD subjects undergoing ACT.
While the results indicate a significant improvement in stress and other psychological indices, there are no previous ACT studies in IBD populations with which to compare the present results.
However, several studies have assessed an allied therapy, CBT, in IBD populations. The aim of CBT is to modify negative thoughts, feelings, and behaviors and replace them with more positive views, thereby decreasing emotional distress, improving some quality of life domains and M A N U S C R I P T
increasing treatment adherence (15, 44) . ACT and CBT have differing analytical approaches, but the two treatments are also similar in many ways so that some comparison can be attempted.
Based on a review of five small studies conducted on a total of 170 subjects, Knowles et al. concluded that CBT had little effect in reducing IBD symptoms or improving overall quality of life, but promising evidence for improving mental health in the short and medium term (17), while Keefer et al. also acknowledge the benefits of CBT in various gastroenterological conditions (15) .
A more recent randomized controlled trial of 118 IBD subjects found that anxiety, depression and quality of life improved in those allocated to CBT when compared with waiting list controls, although stress was not specifically assessed in that study (45) . The present results suggest that an eight-week ACT program has similar effects on comparable mental health indices to that of an eight-week CBT course.
The present study has several strengths. It was adequately powered for primary outcome measurement and only subjects with inactive or mildly active disease on stable maintenance therapies were included to minimize the interaction on stress between the effect of ACT therapy and the confounding effect of improving IBD activity due to concomitant administration of new medical treatments. In addition, subjects with co-existing psychiatric disease, on antidepressant or steroid medications or previously exposed to psychological therapies were excluded, further reducing potential bias, while the study used validated psychological instruments and both subjective and objective measures of disease activity. The pre-defined statistical analysis was performed using a two-way repeated-measures analysis of variance. this is a robust statistical test for follow up trials, capable of assessing data at multiple time-points while correcting for baseline differences between study groups. However, it necessarily excludes those cases with missing data. To facilitate a complete case intention to treat analysis with a withdrawal rate of up to 40 percent, the investigators recruited 122 subjects rather than the 72 specified by the power calculation. There were seven fewer withdrawals than expected so that the primary analysis included 79 with complete psychological data and excluded 21 who withdrew and a further 22 who missed a single study visit. An exploratory analysis, using a last observation carried forward method to impute missing data for these 22 subjects (46), was subsequently performed so that all 101 cases with either partial or full follow-up data could be assessed. Those results were similar in direction and magnitude to the primary analysis (see Supplementary Table 1) . Finally, 28 percent of the study cohort had undergone a previous bowel resection, 35% were on immune modulators and 25% on biologic agents, indicating the presence of a significant disease burden in many, and these data are likely a fair representation of illness severity in IBD cohorts that hospital-based gastroenterologists see in practice.
There are also several limitations to this study. First, it was not possible to blind participants to their allocated group. To minimize bias, an investigator not involved in recruitment or screening M A N U S C R I P T
performed randomization, while subjects completed all study questionnaires alone. Second, it is not possible to determine if the improvements seen in stress and depression levels at eight weeks and maintained at 20 weeks will ultimately translate into a long-term psychological benefit for subjects. Third, as a more general limitation, the results of all psychological research studies can be difficult to reproduce. A large collaborative enterprise that attempted to duplicate 100 separate psychological studies found that the 95% confidence intervals of the replication study included the mean effect size of the original study in less than half of cases (47) . The present study protocol, as with most multiple-attendance randomized controlled trials of psychological interventions (48, 49) , specified a treatment as usual control group to avoid the ethical, work related and financial concerns relating to a multiple attendance sham intervention group. In contrast to treatment as usual controls, sham conditions may be less credible to subjects than active interventions, leading to participant frustration, study fatigue, high withdrawal rates and poor outcomes in the control group (48, 49) thereby falsely inflating the value of the active intervention and compromising study validity. The control group subjects in the present study experienced positive, though nonsignificant, effects in all psychological indices, with improvements of between 4% and 22% at week 20, likely because of increased attention during the trial. Finally, in contrast to drug trials, with their large emphasis on medication quality control, it is difficult to evaluate the quality of psychological interventions or simulate their mode of delivery, and researchers acknowledge this as a significant experimental limitation (16, 17, 47) . The present program used only carefully designed and well documented exercises and learning techniques to maximize reproducibility. In addition, a single psychologist with specialist ACT qualifications, who was also being evaluated by a second psychologist at each session, provided all interventions. This was considered important to enhance intra-program integrity and fidelity across a new procedure, although it necessarily prevented the effect of the intervention being detached from the psychologist providing it.
Further research should evaluate the longer-term efficacy of ACT in IBD populations and compare this intervention to allied therapies. In addition, many patients and health care professionals believe that stress is causally associated with IBD activity (5, 6) , and this hypothesis is supported by a recent study indicating a significant bi-directional brain-gut axis interaction in IBD patients (12) . In this regard, it would be useful to nest appropriate psychological interventions, such as ACT and CBT, into future randomized controlled drug trials to clarify any direct additive effect on subsequent disease activity. Previous research also indicates that ACT increases treatment adherence in some chronic diseases, including diabetes and HIV (50, 51) , and it is possible that further indirect positive treatment effects on disease activity might accrue to Crohn's disease and ulcerative colitis drug trial subjects if this were the case for IBD patients.
What is the value of these results? From a scientific standpoint, the study presents the first evidence that hair cortisol concentrations relate to psychological disability in IBD subjects and, M A N U S C R I P T
while no appreciable changes were seen in cortisol levels over the follow-up period, the results provide a platform for further objective stress studies in IBD populations. From a clinical perspective, IBD care paradigms are moving towards personalized patient centered models that are endorsed by gastroenterologists and psychologists (12, 15, 52, 53) , and both American and European Crohn's and Colitis Organizations (14, 54) . These recommend provision of psychological services within a multidisciplinary framework to treat a range of psychosocial disabilities.
Notwithstanding this, present recommendations are necessarily somewhat generic because of a lack of appropriate randomized controlled trials of potential therapies in IBD populations. The present results demonstrate that an 8-week ACT intervention improves stress and other mental health indices, emphasizing the need for researchers and clinicians to further develop and optimize the content and delivery of psychological programs for IBD patients. Symptom burden* 34 (7) 32 (8) 25 (8) 27 (7) 25 (7) 24 (8) 0.256 27 (7) 25 (7) 23 (7) 0.440 Activities of daily life* 36 (8) 32 (8) 29 (8) 35 (8) 28 (8) 29 (9) 0.515 36 (8) 27 (8) 29 (10) 0.424 Disease-related worry* 51 (8) 43 (8) 40 (8) 53 (8) 39 (9) 33 (9) 0.236 54 (8) 36 (10) 31 (9) 0.052 General well-being* 42 (7) 41 (6) 37 (8) 46 (6) 33 (6) 32 (7) 0.069 47 (7) 31 (6) 29 ( 
